Development of transplantation therapy for genetic liver disorders with hiPSC-derived proliferative hepatoblast

• Project/Area Number: 23K08045
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: The University of Tokyo
• Principal Investigator: 聶 運中 東京大学, 医科学研究所, 助教 (00831330)
• Project Period (FY): 2023-04-01 – 2026-03-31
• Project Status: Granted (Fiscal Year 2023)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2025: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2024: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2023: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: hiPSC / Hepatoblast / Liver repopulation / Genetic liver disorders / Transplantation

Outline of Research at the Start

In this project, we will improve the repopulation capacity of hepatoblast in TK-NOG mice, investigate how to engraft hepatoblast in the liver with our advanced mice models with urea cycle disorders, evaluate the therapeutic effects of hepatoblast transplantation on urea cycle disorders, and apply this transplantation therapy to the treatment of other genetic liver disorders.